1-8 of 8
Jeff P. Sharman
Close
Sort by
Journal Articles

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Clinical Trials & Observations
Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak, Tanya Siddiqi, Paulo Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3345–3359.
https://doi.org/10.1182/bloodadvances.2023011307
Published: 2024
Includes: Supplemental data
Journal Articles

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Jeff P. Sharman, Danielle Brander, Meghan Gutierrez, Qing Huang, Linda H. Wu, Alex Young, Sandhya Upasani, Maoko Naganuma, Jacqueline C. Barrientos
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4760–4764.
https://doi.org/10.1182/bloodadvances.2022008068
Published: 2023
Includes: Supplemental data
Journal Articles

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Clinical Trials & Observations
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1488–1495.
https://doi.org/10.1182/bloodadvances.2022008344
Published: 2023
Includes: Supplemental data
Journal Articles

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

Anas Younes, John M. Burke, Catherine Diefenbach, Silvia Ferrari, Cyrus Khan, Jeff P. Sharman, Monica Tani, Chaitra Ujjani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Michael Gilbertson
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5659–5667.
https://doi.org/10.1182/bloodadvances.2021006131
Published: 2022
Includes: Supplemental data
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data
Journal Articles

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Clinical Trials & Observations
Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, Sarah M. Gressett Ussery, Mecide Gharibo, Pavel Kiselev, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1407–1418.
https://doi.org/10.1182/bloodadvances.2019001145
Published: 2020
Includes: Supplemental data
Journal Articles

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Clinical Trials & Observations
Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers
Journal: Blood Advances
Blood Adv (2017) 1 (25): 2433–2443.
https://doi.org/10.1182/bloodadvances.2017011262
Published: 2017
Includes: Supplemental data
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data